Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.75 |
| ▸ | CXCR1 | P25024 | 7/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.64 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.64 |
| ▸ | HTR7 | P34969 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29843937 | 0.86 | CXCR2 (1.00) | CXCR2CXCR1CYP2C9SERPINE1ADRA1D | |
| SCHEMBL5954935 | 0.86 | CXCR2 (1.00) | CXCR2CXCR1CYP2C9SERPINE1ADRA1D | |
| SCHEMBL5954897 | 0.82 | CXCR2 (1.00) | CXCR2CXCR1CYP2C9SERPINE1ADRA1D | |
| SCHEMBL4808030 | 0.80 | CXCR2 (0.49) | CXCR2CXCR1CYP2C9SERPINE1ADRA1D | |
| SCHEMBL5954354 | 0.78 | CXCR2 (1.00) | CXCR2CXCR1CYP2C9SERPINE1ADRA1D | |
| SCHEMBL5954925 | 0.75 | CXCR2 (0.83) | CXCR2CXCR1CYP2C9 | |
| SCHEMBL4686262 | 0.74 | CXCR2 (0.75) | CXCR2CXCR1CYP2C9SERPINE1ADRA1D | |
| SCHEMBL4698274 | 0.72 | CXCR2 (0.74) | CXCR2CXCR1CYP2C9SERPINE1ADRA1D | |
| SCHEMBL4687748 | 0.71 | CXCR2 (0.60) | CXCR2CXCR1CYP2C9SERPINE1ADRA1D | |
| SCHEMBL4687691 | 0.71 | CXCR2 (1.00) | CXCR2CXCR1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017098421-A1 | BENZOTHIADIAZINE COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-15 | — | — | WO | claimed |
| US-20060122173-A1 | Il-8 receptor antagonists | BUSCH-PETERSEN JAKOB | 2006-06-08 | — | — | US | claimed |
| WO-2017098421-A1 | BENZOTHIADIAZINE COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| US-20060122173-A1 | Il-8 receptor antagonists | BUSCH-PETERSEN JAKOB | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122173-A1 | Il-8 receptor antagonists | CXCL8, CCR8, IL1RN | CXCR2 9/4885CXCR1 13/4885CYP2C9 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.